Copanlisib (Compound)

Synonyms:Copanlisib, 1032568-63-0, BAY 80-6946, BAY-80-6946, Aliqopa, BAY80-6946, WI6V529FZ9, 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide, Copanlisib (BAY 80-6946), 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide, 2-Amino-N-[2,3-dihydro-7-methoxy-8-[3-(4-morpholinyl)propoxy]imidazo[1,2-c]quinazolin-5-yl]-5-pyrimidinecarboxamide, 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide, Copanlisib [INN], BAY 80-6946 (Copanlisib), copanlisibum, UNII-WI6V529FZ9, 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLIN-4-YLPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL)PYRIMIDINE-5-CARBOXAMIDE, Copanlisib tris-HCl, COPANLISIB [MI], Copanlisib (USAN/INN), Copanlisib [USAN:INN], COPANLISIB [USAN], COPANLISIB [WHO-DD], Copanlisib(BAY80-6946), GTPL7875, SCHEMBL1655478, BAY 80-6946; Copanlisib, BAY-80-6946 tris-HCl, Copanlisib; BAY-80-6946, CHEMBL3218576, SCHEMBL13084037, DTXSID00145728, CHEBI:173077, BCP04754, EX-A2005, BDBM50204093, MFCD18633201, NSC760443, NSC800076, NSC809693, NSC816437, s2802, AKOS025290222, BAY-806946, CS-0741, DB12483, NSC-760443, NSC-800076, NSC-809693, NSC-816437, PB22956, VS-0128, NCGC00346457-01, NCGC00346457-02, NCGC00346457-04, 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide, AC-28438, BAY 80-6946?, BC164810, HY-15346, D10867, Q19903876, 2-AMINO-N-(7-METHOXY-8-(3-(MORPHOLIN-4-YL)PROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL(PYRIMIDINE-5-CARBOXAMIDE, 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1.2-c]quinazolin-5-yl]pyrimidine-5-carboxamide, 2-amino-N-{7-methoxy-8-[3-(morpholin-4-yl)propoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide, 5-PYRIMIDINECARBOXAMIDE, 2-AMINO-N-(2,3-DIHYDRO-7-METHOXY-8-(3-(4-MORPHOLINYL)PROPOXY)IMIDAZO(1,2-C)QUINAZOLIN-5-YL)-

Pubchem:PUBCHEM:24989044

Id:81c80a47-780c-526c-8b92-c4d3d3370521

Description:nan

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Copanlisib's neighborhood in the knowledge graph.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Copanlisib.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Copanlisib.

Results found

Linked to

	Label	Description
	BRD-K24666289-001-02-3 Substance (Entity type)	A Substance
	DCSTRUCT ID 05256 Collection (Entity type)	DrugPage Collection: (DrugCentralID:05256; PubChem_CID:135565596, FILE=drugcentral_drug_05256.json)
	copanlisib (9e021eff-3201-4ecc-846e-0a1008252d1f) Collection (Entity type)	Metadatata for copanlisib
	Copanlisib negatively regulates ELOVL5 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Copanlisib negatively regulates ENO2 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Copanlisib positively regulates C7 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Copanlisib positively regulates SELENOP Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Copanlisib positively regulates DCN Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Copanlisib positively regulates JCHAIN Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Copanlisib negatively regulates ID2 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS